PMID- 34387775
OWN - NLM
STAT- MEDLINE
DCOM- 20211125
LR  - 20211125
IS  - 1534-6315 (Electronic)
IS  - 1529-7322 (Linking)
VI  - 21
IP  - 7
DP  - 2021 Aug 13
TI  - Efficacy and Safety of Prostaglandin D2 Receptor 2 Antagonism with Fevipiprant 
      for Patients with Asthma: a Systematic Review and Meta-analysis of Randomized 
      Controlled Trials.
PG  - 39
LID - 10.1007/s11882-021-01017-8 [doi]
AB  - PURPOSE OF REVIEW: Accumulating evidence has shown that prostaglandin D2 
      (PGD2)-chemoattractant receptor-homologous molecule expressed on Th2 cells 
      (CRTH2) pathway plays an important role in promoting eosinophilic airway 
      inflammation in asthma. We aimed to assess the efficacy and safety of CRTH2 
      antagonist fevipiprant in patients with persistent asthma compared with placebo. 
      RECENT FINDINGS: We identified eligible studies by searching PubMed, EMBASE, the 
      Cochrane Central Register of Controlled Trials and ClinicalTrials.gov. The study 
      was registered as CRD 42020221714 ( http://www.crd.york.ac.uk/PROSPERO ). Ten 
      randomized controlled trials with 7902 patients met our inclusion criteria. A 
      statistically significant benefit of fevipiprant compared with placebo was shown 
      in improving forced expiratory volume in 1 s (MD 0.05 L, 95% CI: 0.02 to 0.07; p 
      < 0.0001), Asthma Control Questionnaire score (MD -0.10, 95% CI: -0.16 to -0.04; 
      p = 0.001), and Asthma Quality of Life Questionnaire score (MD 0.08, 95% CI: 0.03 
      to 0.13; p = 0.003). Fevipiprant decreased number of patients with at least one 
      asthma exacerbation requiring administration of systemic corticosteroids for 3 
      days or more (RR 0.86, 95% CI: 0.77 to 0.97; p = 0.01). Some benefits were a 
      little more pronounced in the high eosinophil population (with an elevated blood 
      eosinophil count or sputum eosinophil percentage) and in the 450 mg dose group. 
      Fevipiprant was well tolerated with no safety issues compared with placebo. 
      Fevipiprant could safely improve asthma outcomes compared to placebo. However, 
      most of the differences didn't reach the minimal clinically important difference 
      (MCID), thus the clinical benefits remained to be confirmed.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer Science+Business 
      Media, LLC, part of Springer Nature.
FAU - Yang, Dan
AU  - Yang D
AD  - Department of Respiratory and Critical Care Medicine, School of Medicine and West 
      China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, 610041, West 
      China, China.
FAU - Guo, Xinning
AU  - Guo X
AD  - Department of Respiratory and Critical Care Medicine, School of Medicine and West 
      China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, 610041, West 
      China, China.
FAU - Liu, Ting
AU  - Liu T
AD  - Department of Respiratory and Critical Care Medicine, School of Medicine and West 
      China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, 610041, West 
      China, China.
FAU - Li, Yina
AU  - Li Y
AD  - Department of Respiratory and Critical Care Medicine, School of Medicine and West 
      China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, 610041, West 
      China, China.
FAU - Du, Zhuman
AU  - Du Z
AD  - Department of Respiratory and Critical Care Medicine, School of Medicine and West 
      China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, 610041, West 
      China, China.
FAU - Liu, Chuntao
AU  - Liu C
AD  - Department of Respiratory and Critical Care Medicine, School of Medicine and West 
      China Hospital, Sichuan University, No.37 Guoxue Alley, Chengdu, 610041, West 
      China, China. liuchuntaoscu@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20210813
PL  - United States
TA  - Curr Allergy Asthma Rep
JT  - Current allergy and asthma reports
JID - 101096440
RN  - 0 (Anti-Asthmatic Agents)
RN  - 0 (Indoleacetic Acids)
RN  - 0 (Pyridines)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Receptors, Prostaglandin)
RN  - 2PEX5N7DQ4 (fevipiprant)
RN  - XZF106QU24 (prostaglandin D2 receptor)
SB  - IM
MH  - *Anti-Asthmatic Agents/therapeutic use
MH  - *Asthma/diagnosis/drug therapy
MH  - Humans
MH  - Indoleacetic Acids
MH  - Pyridines
MH  - Quality of Life
MH  - Randomized Controlled Trials as Topic
MH  - Receptors, Immunologic
MH  - Receptors, Prostaglandin
OTO - NOTNLM
OT  - Asthma
OT  - Biologics
OT  - DP2 receptor
OT  - Fevipiprant
OT  - Prostaglandin D2
OT  - Randomized controlled trials
EDAT- 2021/08/14 06:00
MHDA- 2021/11/26 06:00
CRDT- 2021/08/13 12:21
PHST- 2021/07/01 00:00 [accepted]
PHST- 2021/08/13 12:21 [entrez]
PHST- 2021/08/14 06:00 [pubmed]
PHST- 2021/11/26 06:00 [medline]
AID - 10.1007/s11882-021-01017-8 [pii]
AID - 10.1007/s11882-021-01017-8 [doi]
PST - epublish
SO  - Curr Allergy Asthma Rep. 2021 Aug 13;21(7):39. doi: 10.1007/s11882-021-01017-8.